Archive for NIAID

Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial for the treatment of Psoriasis with (L/D)-Aminopterin

Congratulations to Syntrix scientists on their new grant for $1.725M from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).  The project title is “Efficacy and Resistance Mechanisms of (L/D)-Aminopterin in Psoriasis.”  Here is the public health relevance from the proposal:  “Psoriasis is a chronic scaly and inflammatory […]

Collaboration: Syntrix Receives $557K Grant to Develop New Drug for Multiple Drug Resistant Tuberculosis

Syntrix scientists will collaborate with Dr. Andrew Bognar of the University of Toronto on a $557K tuberculosis grant from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The project title is “Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB.” The public health relevance from the proposal: “Multidrug-resistant tuberculosis and extensively drug […]